Dana L Casey1, Brian H Kushner2, Nai-Kong V Cheung2, Shakeel Modak2, Michael P LaQuaglia3, Suzanne L Wolden4. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: woldens@mskcc.org.
Abstract
PURPOSE: To evaluate local control after 21-Gy radiation therapy (RT) to the primary site in patients with high-risk neuroblastoma. METHODS AND MATERIALS: After receiving dose-intensive chemotherapy and gross total resection (GTR), 246 patients (aged 1.2-17.9 years, median 4.0 years) with high-risk neuroblastoma underwent RT to the primary site at Memorial Sloan Kettering from 2000 to 2014. Radiation therapy consisted of 21 Gy in twice-daily fractions of 1.5 Gy each. Local failure (LF) was correlated with biologic prognostic factors and clinical findings at the time of diagnosis and start of RT. RESULTS: Median follow-up of surviving patients was 6.4 years. Cumulative incidence of LF was 7.1% at 2 years after RT and 9.8% at 5 years after RT. The isolated LF rate was 3.0%. Eighty-six percent of all local failures were within the RT field. Local control was worse in patients who required more than 1 surgical resection to achieve GTR (22.4% vs 8.3%, P=.01). There was also a trend toward inferior local control with MYCN-amplified tumors or serum lactate dehydrogenase ≥1500 U/L (P=.09 and P=.06, respectively). CONCLUSION: After intensive chemotherapy and maximal surgical debulking, hyperfractionated RT with 21 Gy in high-risk neuroblastoma results in excellent local control. Given the young patient age, concern for late effects, and local control >90%, dose reduction may be appropriate for patients without MYCN amplification who achieve GTR.
PURPOSE: To evaluate local control after 21-Gy radiation therapy (RT) to the primary site in patients with high-risk neuroblastoma. METHODS AND MATERIALS: After receiving dose-intensive chemotherapy and gross total resection (GTR), 246 patients (aged 1.2-17.9 years, median 4.0 years) with high-risk neuroblastoma underwent RT to the primary site at Memorial Sloan Kettering from 2000 to 2014. Radiation therapy consisted of 21 Gy in twice-daily fractions of 1.5 Gy each. Local failure (LF) was correlated with biologic prognostic factors and clinical findings at the time of diagnosis and start of RT. RESULTS: Median follow-up of surviving patients was 6.4 years. Cumulative incidence of LF was 7.1% at 2 years after RT and 9.8% at 5 years after RT. The isolated LF rate was 3.0%. Eighty-six percent of all local failures were within the RT field. Local control was worse in patients who required more than 1 surgical resection to achieve GTR (22.4% vs 8.3%, P=.01). There was also a trend toward inferior local control with MYCN-amplified tumors or serum lactate dehydrogenase ≥1500 U/L (P=.09 and P=.06, respectively). CONCLUSION: After intensive chemotherapy and maximal surgical debulking, hyperfractionated RT with 21 Gy in high-risk neuroblastoma results in excellent local control. Given the young patient age, concern for late effects, and local control >90%, dose reduction may be appropriate for patients without MYCN amplification who achieve GTR.
Authors: Lillian R Meacham; Charles A Sklar; Suwen Li; Qi Liu; Nora Gimpel; Yutaka Yasui; John A Whitton; Marilyn Stovall; Leslie L Robison; Kevin C Oeffinger Journal: Arch Intern Med Date: 2009-08-10
Authors: Rani E George; Shuli Li; Cheryl Medeiros-Nancarrow; Donna Neuberg; Karen Marcus; Robert C Shamberger; Michael Pulsipher; Stephan A Grupp; Lisa Diller Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: Susan G Kreissman; Robert C Seeger; Katherine K Matthay; Wendy B London; Richard Sposto; Stephan A Grupp; Daphne A Haas-Kogan; Michael P Laquaglia; Alice L Yu; Lisa Diller; Allen Buxton; Julie R Park; Susan L Cohn; John M Maris; C Patrick Reynolds; Judith G Villablanca Journal: Lancet Oncol Date: 2013-07-25 Impact factor: 41.316
Authors: Nai-Kong V Cheung; Irene Y Cheung; Brian H Kushner; Irina Ostrovnaya; Elizabeth Chamberlain; Kim Kramer; Shakeel Modak Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Maria Antonietta De Ioris; Alessandro Crocoli; Benedetta Contoli; Maria Carmen Garganese; Gianluigi Natali; Paolo Tomà; Alessandro Jenkner; Renata Boldrini; Maria Debora De Pasquale; Giuseppe Maria Milano; Silvia Madafferi; Aurora Castellano; Franco Locatelli; Alessandro Inserra Journal: BMC Cancer Date: 2015-02-21 Impact factor: 4.430
Authors: Marjolein van Waas; Sebastian J C M M Neggers; Hein Raat; Caroline M van Rij; Rob Pieters; Marry M van den Heuvel-Eibrink Journal: PLoS One Date: 2012-12-14 Impact factor: 3.240
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-11 Impact factor: 7.038
Authors: Thomas H Beckham; Dana L Casey; Michael P LaQuaglia; Brian H Kushner; Shakeel Modak; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-11 Impact factor: 7.038
Authors: Dana L Casey; Ken L Pitter; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 7.038
Authors: Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038
Authors: Alexander F Bagley; David R Grosshans; Nancy V Philip; Jennifer Foster; Mary Frances McAleer; Susan L McGovern; Yasmin Lassen-Ramshad; Anita Mahajan; Arnold C Paulino Journal: Pediatr Blood Cancer Date: 2019-05-02 Impact factor: 3.167
Authors: John T Lucas; M Beth McCarville; David A Cooper; Mikhail Doubrovin; Daniel Wakefield; Teresa Santiago; Yimei Li; Xingyu Li; Matthew Krasin; Victor Santana; Wayne Furman; Andrew M Davidoff Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-26 Impact factor: 7.038
Authors: Annu Singh; Shakeel Modak; Armand K Solano; Brian H Kushner; Suzanne Wolden; Joseph Huryn; Cherry L Estilo Journal: Pediatr Blood Cancer Date: 2021-01-28 Impact factor: 3.167
Authors: Ji Hwan Jo; Seung Do Ahn; Minji Koh; Jong Hoon Kim; Sang-Wook Lee; Si Yeol Song; Sang Min Yoon; Young Seok Kim; Su Ssan Kim; Jin-Hong Park; Jinhong Jung; Eun Kyung Choi Journal: Radiat Oncol J Date: 2019-09-30